The novel cannabinoid CB1 antagonist AM6545 suppresses food intake and food-reinforced behavior

Pharmacology Biochemistry and Behavior

Volumn 97, Issue 1, 2010, Pages 179-184

  Randall, P A ^a   Vemuri, V K ^b   Segovia, K N ^a   Torres, E Ferreris ^a   Hosmer, S ^a   Nunes, E J ^a   Santerre, J L ^a   Makriyannis, A ^b   Salamone, J D ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b NORTHEASTERN UNIVERSITY   (United States)

Author keywords

Appetite; Feeding; Motivation; Operant; Rimonabant; THC

Indexed keywords

5 [4 (4 CYANOBUT 1 YNYL)PHENYL] 1 (2,4 DICHLOROPHENYL) 4 METHYL N (1,1 DIOXO THIOMORPHOLINO) 1H PYRAZOLE 3 CARBOXAMIDE; AM 6545; ANOREXIGENIC AGENT; CANNABINOID 1 RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ARTICLE; CARBOHYDRATE DIET; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DRUG PENETRATION; DRUG SYNTHESIS; FEEDING BEHAVIOR; FOOD INTAKE; INSTRUMENTAL CONDITIONING; LIPID DIET; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; APPETITE DEPRESSANTS; DIETARY CARBOHYDRATES; DIETARY FATS; EATING; FEEDING BEHAVIOR; MALE; MORPHOLINES; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, CANNABINOID, CB1; REINFORCEMENT (PSYCHOLOGY);

EID: 77957749920     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2010.07.021     Document Type: Article

References (42)

1. Addy C., Rothenberg P., Li S., Majumdar A., Agrawal N., Li H., et al. Multiple-dose pharmacokinetics, pharmacodynamics, and safety of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, in healthy male volunteers. J Clin Pharmacol 2008, 48:734-744.
2. Arnone M., Maruani J., Chaperon F., Thiébot M.-H., Poncelet M., Soubrié P., et al. Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors. Psychopharmacology 1997, 132:104-106.
3. Blundell J.E. Serotonin manipulations and the structure of feeding behaviour. Appetite 1986, 7(Suppl):39-56.
4. Blundell J.E., Latham C.J. Characterisation of adjustments to the structure of feeding behaviour following pharmacological treatment: effects of amphetamine and fenfluramine and the antagonism produced by pimozide and methergoline. Pharmacol Biochem Behav 1980, 12:717-722.
5. Chambers A.P., Vemuri V.K., Peng Y., Wood J.T., Olszewska T., Pittman Q.J., et al. A neutral CB1 receptor antagonist reduces weight gain in rat. Am J Physiol Regul Integr Comp Physiol 2007, 293:R2185-R2193.
6. 1) receptor antagonist AM6545 reduces food intake and body weight, but does not cause malaise, in rodents. Brit J Pharmacol 2010, 161:629-642.
7. Colombo G., Agabio R., Diaz G., Lobina C., Reali R., Gessa G.L. Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. Life Sci 1998, 63:PL113-PL117.
8. Cooper S.J. Endocannabinoids and food consumption: comparisons with benzodiazepine and opioid palatability-dependent appetite. Eur J Pharmacol 2004, 500:37-49.
9. Curioni C., Andre C. Rimonabant for overweight or obesity. Cochrane Database Syst Rev 2006, 4:CD006162.
10. Despres JP, Golay A, Sjostrom L. Rimonabant in Obesity-Lipids Study Group, 2005. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2006; 353: 2121-2134.
11. Freedland C.S., Poston J.S., Porrino L.J. Effects of SR141716A, a central cannabinoid receptor antagonist, on food-maintained responding. Pharmacol Biochem Behav 2000, 67:265-270.
12. Gardner A., Mallet P.E. Suppression of feeding, drinking, and locomotion by a putative cannabinoid receptor 'silent antagonist'. Eur J Pharmacol 2006, 530:103-106.
13. Gomez R., Navarro M., Ferrer B., Trigo J.M., Bilbao A., Del Arco I., et al. A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. J Neurosci 2002, 22:9612-9617.
14. Higgs S., Williams C.M., Kirkham T.C. Cannabinoid influences on palatability: microstructural analysis of sucrose drinking after delta(9)-tetrahydrocannabinol, anandamide, 2-arachidonoyl glycerol and SR141716. Psychopharmacology 2003, 165(4):370-377.
15. Hodge J., Bow J.P., Plyler K.S., Vemuri V.K., Wisniecki A., Salamone J.D., et al. The cannabinoid CB1 receptor inverse agonist AM 251 and antagonist AM 4113 produce similar effects on the behavioral satiety sequence in rats. Behav Brain Res 2008, 193:298-305.
16. Jamshidi N., Taylor D.A. Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats. Br J Pharmacol 2001, 134:1151-1154.
17. Keppel G. Design and analysis: a researchers handbook 1982, Prentice-Hall, Englewood Cliffs, NJ.
18. Kirkham T.C., Williams C.M., Fezza F., Di Marzo V. Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br J Pharmacol 2002, 136:550-557.
19. Le Foll B., Gorelick D.A., Goldberg S.R. The future of endocannabinoid-oriented clinical research after CB1 antagonists. Psychopharm (Berl) 2009, 205:171-174.
20. McLaughlin P.J., Winston K., Swezey L., Wisniecki A., Aberman J., Tardif D.J., et al. The cannabinoid CB1 antagonists SR 141716A and AM 251 suppress food intake and food-reinforced behavior in a variety of tasks in rats. Behav Pharmacol 2003, 14:583-588.
21. McLaughlin P.J., Winston K.M., Limebeer C.L., Parker L.A., Makriyannis A., Salamone J.D. The cannabinoid CB1 antagonist AM251 produces food avoidance and behaviors associated with nausea but does not impair feeding efficiency in rats. Psychopharmacology 2005, 180:286-293.
22. McLaughlin P.J., Qian L., Wood J.T., Wisniecki A., Winston K.M., Swezey L.A., et al. Suppression of food intake and food-reinforced behavior produced by the novel CB1 receptor antagonist/inverse agonist AM1387. Pharmacol Biochem Behav 2006, 83:396-402.
23. Pi-Sunyer F.X., Aronne L.J., Heshmati H.M., Devin J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006, 295:761-775. RIO-North America Study Group.
24. Rodgers R.J., Evans P.M., Murphy A. Anxiogenic profile of AM-251, a selective cannabinoid CB1 receptor antagonist, in plus-maze-naïve and plus-maze-experienced mice. Behav Pharmacol 2005, 16:405-413.
25. Salamone J.D., Zigmond M.J., Stricker E.M. Characterization of the impaired feeding behavior in rats given haloperidol or dopamine-depleting brain lesions. Neuroscience 1990, 39:17-24.
26. Salamone J.D., Mahan K., Rogers S. Ventrolateral striatal dopamine depletions impair feeding and food handling in rats. Pharmacol Biochem Behav 1993, 44:605-610.
27. Salamone J.D., McLaughlin P.J., Sink K., Makriyannis A., Parker L.A. Cannabinoid CB(1) receptor inverse agonists and neutral antagonists: effects on food intake, food-reinforced behavior and food aversions. Physiol Behav 2007, 91:383-388.
28. Simiand J., Keane M., Keane P.E., Soubrie P. SR141716, a CB1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset. Behav Pharmacol 1998, 9:179-181.
29. Sink K.S., McLaughlin P.J., Wood J.A., Brown C., Fan P., Vemuri V.K., et al. The novel cannabinoid CB(1) receptor neutral antagonist AM4113 suppresses food intake and food-reinforced behavior but does not induce signs of nausea in rats. Neuropsychopharmacology 2008, 43:946-955.
30. Sink K.S., Vemuri V.K., Olszewska T., Makriyannis A., Salamone J.D. Cannabinoid CB1 antagonists and dopamine antagonists produce different effects on a task involving response allocation and effort-related choice in food-seeking behavior. Psychopharmacology 2008, 196:565-574.
31. Sink K.S., Vemuri V.K., Wood J., Makriyannis A., Salamone J.D. Oral bioavailability of the novel cannabinoid CB1 antagonist AM6527: effects on food-reinforced behavior and comparisons with AM4113. Pharmacol Biochem Behav 2009, 91:303-306.
32. Sink K.S., Segovia K.N., Nunes E.J., Collins L.E., Vemuri V.K., Thakur G., et al. Intracerebroventricular administration of cannabinoid CB1 receptor antagonists AM251 and AM4113 fails to alter food-reinforced behavior in rats. Psychopharmacology 2009, 206:223-232.
33. Sink K.S., Segovia K.N., Sink J., Randall P.A., Collins L.E., Correa M., et al. Potential anxiogenic effects of cannabinoid CB1 receptor antagonists/inverse agonists in rats: comparisons between AM4113, AM251, and the benzodiazepine inverse agonist FG-7142. Eur Neuropsychopharmacol 2010, 20:112-122.
34. Sink KS, Segovia KN, Collins LE, Markus EJ, Vemuri VK, Makriyannis A, Salamone JD. The CB1 inverse agonist AM251, but not the CB1 antagonist AM4113, enhances retention of contextual fear conditioning in rats. Pharmacol Biochem Behav 2010:95:479-84.
35. Tallett A.J., Blundell J.E., Rodgers J.R. Acute anorectic response to cannabinoid CB1 receptor antagonist/inverse agonist AM 251 in rats: indirect behavioural mediation. Behav Pharmacol 2007, 18:591-600.
36. Tallett A.J., Blundell J.E., Rodgers R.J. Grooming, scratching and feeding: role of response competition in acute anorectic response to rimonabant in male rats. Psychopharmacology 2007, 195:27-39.
37. Thornton-Jones Z.D., Vickers S.P., Clifton P.G. The cannabinoid CB1 receptor antagonist SR141716A reduces appetitive and consummatory responses for food. Psychopharmacology 2005, 179:452-460.
38. Thornton-Jones Z.D., Kennett G.A., Vickers S.P., Clifton P.G. A comparison of the effects of the CB(1) receptor antagonist SR141716A, pre-feeding and changed palatability on the microstructure of ingestive behaviour. Psychopharmacology 2007, 193:1-9.
39. US Food and Drug Administration Advisory Committee. FDA briefing document: zimulti (rimonabant) Tablets, 20mg, FDA, Rockville. [WWW document]. URL (). 2007. http://www.fda.gov/OHRMS/DOCKETS/AC/07/briefing/2007-4306b1-00-index.htm.
40. Van Gaal L.F., Rissanen A.M., Scheen A.J., Ziegler O. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005, 365:1389-1397. RIO-Europe Study Group.
41. Ward S.J., Dykstra L.A. The role of CB1 receptors in sweet versus fat reinforcement: effect of CB1 receptor deletion, CB1 receptor antagonism (SR141716A) and CB1 receptor agonism (CP-55940). Behav Pharmacol 2005, 16:381-388.
42. Williams C.M., Kirkham T.C. Anandamide induces overeating: mediation by central cannabinoid (CB1) receptors. Psychopharmacology 1999, 143:315-317.